In a Phase I dose-expansion clinical trial of trastuzumab duocarmazine in patients with HER2-expressing breast, gastric, urothelial, or endometrial cancer, 146 patients were enrolled, 14 of them with endometrial cancer. The gene discussed is ERBB2; the disease is endometrial cancer.